Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil's President Eases Compulsory Licensing Law On Pandemic-Related Products

Executive Summary

Companies in Brazil will not have to provide know-how and other detailed information on patents that are subject to compulsory licenses during national or international emergencies, although other provisions of a law passed last year to ease the compulsory licensing process remain in place.

You may also be interested in...



Stakeholders Gather To Discuss Pandemic Response And Next Steps

As Europe’s health emergency body HERA approaches its first anniversary, an unprecedented range of stakeholders including industry bodies will be meeting in December to discuss HERA’s achievements, while a separate event will showcase the next generation of vaccines for COVID-19 and other infections.

EU Wants Legislative Review To Support ‘World Class’ Pharmaceutical Industry

The European health commissioner has told members of parliament that a balance needs to be struck between promoting innovation and maximizing access to medicines across the EU member states.

WHO Gives Strong Backing To Antimalarial Combo As New Resistance Strategy Kicks Off

Hot on the heels of its new antimalarial strategy, the World Health Organization has given a “strong” recommendation for the use of a fixed-dose artemisinin combination therapy from Shin Poong and the Medicines for Malaria Venture that should see it being more widely used in disease-endemic countries.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel